Donald Chase Purchases 12,500 Shares of Bluejay Diagnostics (NASDAQ:BJDX) Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Donald Chase bought 12,500 shares of the business’s stock in a transaction on Saturday, March 14th. The shares were bought at an average price of $2.00 per share, for a total transaction of $25,000.00. Following the completion of the acquisition, the director owned 12,525 shares of the company’s stock, valued at approximately $25,050. This represents a 50,000.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

Bluejay Diagnostics Price Performance

BJDX traded up $0.05 on Monday, hitting $1.72. The company had a trading volume of 34,940 shares, compared to its average volume of 155,600. The stock has a market cap of $1.77 million, a price-to-earnings ratio of -0.15 and a beta of 0.72. The company’s fifty day moving average price is $1.90 and its 200 day moving average price is $3.24. Bluejay Diagnostics, Inc. has a 1-year low of $1.63 and a 1-year high of $16.68.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is owned by institutional investors and hedge funds.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.